Market Place
Sourcing Support
Scynexis Reports Q3 2024 Financials & Corporate Update
06 Nov 2024 //
GLOBENEWSWIRE
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
10 Oct 2024 //
GLOBENEWSWIRE
SCYNEXIS To Present SCY-247 Data At IDWeek 2024
03 Oct 2024 //
GLOBENEWSWIRE
SCYNEXIS To Participate In H.C. Wainwright Investment Conference
27 Aug 2024 //
GLOBENEWSWIRE
SCYNEXIS Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
SCYNEXIS To Receive $10M Milestone From GSK For Clinical Study Reports
23 Jul 2024 //
GLOBENEWSWIRE
SCYNEXIS Q1 2024 Results, Corporate Update
08 May 2024 //
GLOBENEWSWIRE
SCYNEXIS Presents Preclinical Data On Fungerp SCY-247 At ESCMID
30 Apr 2024 //
GLOBENEWSWIRE
SCYNEXIS Presents SCY-247 Data at the 34th ECCMID
09 Apr 2024 //
GLOBENEWSWIRE
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 2024 //
GLOBENEWSWIRE
SCYNEXIS to Participate in Guggenheim™s 6th Annual Biotechnology Conference
30 Jan 2024 //
GLOBENEWSWIRE
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247
29 Jan 2024 //
GLOBENEWSWIRE
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247
05 Jan 2024 //
GLOBENEWSWIRE
GSK amends deal with Scynexis amid Brexafemme manufacturing woes
03 Jan 2024 //
FIERCE PHARMA
SCYNEXIS Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of October 18, 2023
18 Oct 2023 //
FDA
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247
16 Oct 2023 //
GLOBENEWSWIRE
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME
27 Sep 2023 //
GLOBENEWSWIRE
Scynexis to recall GSK-partnered antifungal on cross contamination risk
25 Sep 2023 //
REUTERS
SCYNEXIS to Participate in September Investor Conferences
28 Aug 2023 //
GLOBENEWSWIRE
SCYNEXIS Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
SCYNEXIS and Hansoh Announce NMPA Acceptance of NDA for Ibrexafungerp
20 Jul 2023 //
GLOBENEWSWIRE
SCYNEXIS Achieves $25M GSK Development Milestone
21 Jun 2023 //
CONTRACTPHARMA
SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
15 Jun 2023 //
GLOBENEWSWIRE
SCYNEXIS Reports Closing of Agreement with GSK for BREXAFEMME
12 May 2023 //
GLOBENEWSWIRE
SCYNEXIS Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Scynexis to Present Ibrexafungerp Data at the 33rd Annual ECCMID April 15-18
13 Apr 2023 //
GLOBENEWSWIRE
SCYNEXIS Reports 4Q & 2022 Financial Results orporate Update
31 Mar 2023 //
GLOBENEWSWIRE
GSK and Scynexis announce an exclusive agreement to commercialise Brexafemme
31 Mar 2023 //
PRESS RELEASE
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME®
01 Dec 2022 //
GLOBENEWSWIRE
SCYNEXIS Announces $3 M National Institutes of Health Grant Has Been Awarded
30 Nov 2022 //
GLOBENEWSWIRE
BARDA Invests in Development of Antifungal Treatments
18 Nov 2022 //
CONTRACTPHARMA
SCYNEXIS Applauds the (BARDA) for Its New Priority Focus on Investment
17 Nov 2022 //
GLOBENEWSWIRE
SCYNEXIS Reports Third Quarter 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp
07 Nov 2022 //
GLOBENEWSWIRE
Pooled Data from the Pivotal Ph3 VANISH Program Published of Women’s Health
03 Nov 2022 //
GLOBENEWSWIRE
SCYNEXIS to Report 3Q 2022 FYR and Provide a Corporate Update on November 9
01 Nov 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp
24 Oct 2022 //
GLOBENEWSWIRE
SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates
20 Oct 2022 //
GLOBENEWSWIRE
Scynexis to out license sole commercial med and cut sales team
20 Oct 2022 //
FIERCEPHARMA
SCYNEXIS to Present Positive Interim Data from the Phase 3
11 Oct 2022 //
GLOBENEWSWIRE
SCYNEXIS to Participate in Upcoming September Investor Conferences
09 Sep 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Interim Data of Ibrexafungerp Ongoing Phase 3
08 Sep 2022 //
GLOBENEWSWIRE
SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four
01 Sep 2022 //
GLOBENEWSWIRE
SCYNEXIS Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
SCYNEXIS to Report Second Quarter 2022 Financial results
09 Aug 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Data from PIII CANDLE Study of Oral Ibrexafungerp
04 Aug 2022 //
GLOBENEWSWIRE
SCYNEXIS Announces FDA Acceptance and Priority Review of sNDA for BREXAFEMME
01 Aug 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Data from PIII CANDLE Nested Study of Ibrexafungerp
19 Jul 2022 //
GLOBENEWSWIRE
SCYNEXIS to Present Data from CANDLE Nested Sub-Study of Ibrexafungerp
14 Jul 2022 //
GLOBENEWSWIRE
SCYNEXIS Initiates New PIIIb Study (VANQUISH) for Oral Ibrexafungerp in WC
23 Jun 2022 //
GLOBENEWSWIRE
SCYNEXIS Submits sNDA of BREXAFEMME to FDA for Vaginal Yeast Infections
08 Jun 2022 //
GLOBENEWSWIRE
SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Scynexis rolls out new Brexafemme marketing — and rallying cry
12 May 2022 //
ENDPTS
SCYNEXIS Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for rVC
10 May 2022 //
GLOBENEWSWIRE
SCYNEXIS to Report First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
SCYNEXIS to Present New Data of Ibrexafungerp for Vulvovaginal Candidiasis
04 May 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp`s Potential
27 Apr 2022 //
GLOBENEWSWIRE
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock
26 Apr 2022 //
GLOBENEWSWIRE
